• Newly treated female patients aged ≥18 years and ≤75 years;

• ECOG score 0\

∙ 1;

• Pathologically diagnosed as HER2-positive breast cancer patients with early or locally advanced tumor stage, primary tumor diameter T≥2cm or lymph node positive;

• Hormone receptor status (ER and PgR) is known, where ER≥10%

• Normal function of major organs:

‣ The standard of blood routine examination should meet: ANC ≥1.5×109/L; PLT≥90×109/L; Hb ≥90g/L

⁃ Biochemical examination should meet the following standards: TBIL≤ the upper limit of normal value(ULN); ALT and AST≤1.5 times the upper limit of normal (ULN); Alkaline phosphatase ≤2.5 times the upper limit of normal (ULN); BUN and Cr≤1.5×ULN and creatinine clearance ≥50 mL/min (CockcroftGault formula);

⁃ Cardiac color ultrasound and echocardiography: left ventricular ejection fraction(LVEF≥55%)

⁃ Fridericia calibrated QT interval (QTcF) for 18-lead ECG \<470 ms;

• For female patients who are not menopausal or have not been surgically sterilized: consent to abstinence or use of an effective contraceptive method during treatment and for at least 7 months after the last dose in the study treatment;

• Volunteer to join the study and sign the informed consent.